Home › Scleroderma › Arizona › Phoenix
Scleroderma clinical trials in Phoenix, AZ
4 studies for Scleroderma are looking for participants at sites in and around Phoenix (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
RecruitingPhase 2
- Arizona Arthritis and Rheumatology Associates, Phoenix
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
RecruitingPhase 3
- Banner - University Medicine Rheumatology Clinic, Phoenix
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
- Mayo Clinic, Phoenix
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RecruitingPhase 2
- Artiva Investigational Site Phoenix, Phoenix
About Scleroderma
Scleroderma is an autoimmune disease that causes inflammation and thickening in the skin and other areas of the body. The exact cause of scleroderma is unknown.
More about Scleroderma on MedlinePlus
Scleroderma trials in other cities
- New York City, NY11 studies
- Chicago, IL10 studies
- Ann Arbor, MI10 studies
- Houston, TX9 studies
- Boston, MA7 studies
- Durham, NC7 studies
- Los Angeles, CA7 studies
- Philadelphia, PA6 studies
- Baltimore, MD6 studies
- New Orleans, LA6 studies
- Pittsburgh, PA5 studies
- Dallas, TX5 studies
Other studies in Phoenix
- Breast Cancer25 studies
- Colorectal Cancer25 studies
- Obesity23 studies
- Non-Small Cell Lung Cancer21 studies
- Metastatic Cancer20 studies
- Cancer (all types)18 studies
- Heart Failure18 studies
- Prostate Cancer17 studies
- Pancreatic Cancer17 studies
- Cardiovascular Disease16 studies
- Multiple Myeloma16 studies
- Alzheimer's Disease15 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.